Prof. Groop (Helsinki, Finland)

Published 27.05.2021 by Boehringer Ingelheim

Linagliptin for a broad range of patients - spotlight on safety data

Transcript

What about the safety profile? Whenever we prescribe any medications to our patients, we need to be assured that we are not causing harm. And if you compare the profile of linagliptin with placebo, you can see that there is no difference.

Prof. Groop (Helsinki, Finland)

Can a broad range of T2D patients benefit from the simplicity of linagliptin?

Dr. Jarvis (London, England)

Defining simplicity in clinical practice – a case-driven approach.

Prof. Groop (Helsinki, Finland)

Summarising the advances that linagliptin has brought to T2D care.

Prof. Groop (Helsinki, Finland)

Prof. Groop (Helsinki, Finland)

RELATED CONTENT